AUTORES: O. W. Akkerman,1,2 R. Duarte,3 S. Tiberi,4 H. S. Schaaf,5 C. Lange,6,7,8,9 J. W. C. Alffenaar,10,11,12 J. Denholm,13 A. C. C. Carvalho,14 M. S. Bolhuis,15 S. Borisov,16 J. Bruchfeld,17,18 A. M. Cabibbe,19 J. A. Caminero,20,21 I. Carvalho,22 J. Chakaya,23,24 R. Centis,25 M. P. Dalcomo,26 L. D’Ambrosio,27 M. Dedicoat,28 K. Dheda,29,30,31 K. E. Dooley,32 J. Furin,33 J-M. Garc´ıa-Garc´ıa,34 N. A. H. van Hest,2,35 B. C. de Jong,36 X. Kurhasani,37 A. G. M¨artson,38 S. Mpagama,39,40 M. Munoz Torrico,41 E. Nunes,42,43 C. W. M. Ong,44,45,46 D. J. Palmero,47 R. Ruslami,48,49 A. M. I. Saktiawati,50,51 C. Semuto,52 D. R. Silva,53 R. Singla,54 I. Solovic,55 S. Srivastava,56 J. E. M. de Steenwinkel,57 A. Story,58,59 M. G. G. Sturkenboom,15 M. Tadolini,60,61 Z. F. Udwadia,62 A. R. Verhage,63 J. P. Zellweger,64 G. B. Migliori25 *OWA, RD and ST contributed equally. INSTITUIÇÕES: 1TB Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, 2Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 3Centro Hospitalar de Vila Nova de Gaia/Espinho; Instituto de Ciencias Biom´edicas de Abel Saalazar, Universidade do Porto, Instituto de Sa ´ ude Publica da Universidade do Porto, Unidade de Investiga¸ca˜o Cl´ınica, ARS Norte, Porto, Portugal; 4Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK; 5Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; 6Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, 7German Center for Infection Research (DZIF) Clinical Tuberculosis Unit, Borstel, 8Respiratory Medicine & International Health, University of L¨ ubeck, L¨ ubeck, Germany; 9The Global Tuberculosis Program, Texas Children’s Hospital, Immigrant and Global Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; 10Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, 11School of Pharmacy, The University of Sydney Faculty of Medicine and Health, Sydney, NSW, 12Westmead Hospital, Sydney, NSW, 13Victorian Tuberculosis Program, Melbourne Health, Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; 14Laborat ´ orio de Inova¸c ˜ oes em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Funda¸ca˜o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil; 15Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; 16Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia; 17Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Solna, Stockholm, 18Department of Infectious Disease, Karolinska University Hospital, Stockholm, Sweden; 19Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy; 20Department of Pneumology, University General Hospital of Gran Canaria ‘‘Dr Negrin’’, Las Palmas, 21ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain; 22Pediatric Department, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia, Portugal; 23Department of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya; 24Department of Clinical Sciences. Liverpool School of Tropical Medicine, Liverpool, UK; 25Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy; 26Reference Center Helio Fraga, FIOCRUZ, Brazil; 27Public Health Consulting Group, Lugano, Switzerland; 28Department of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 29Centre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, and 30South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa; 31Faculty of Infectious and Tropical Diseases, London School of Hygiene&Tropical Medicine, London, UK; 32Center for Tuberculosis Research, Johns Hopkins, Baltimore, MD, 33Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; 34Tuberculosis Research Programme SEPAR, E-08029 Barcelona, Spain; 35Municipal Public Health Service Groningen, Groningen, The Netherlands; 36Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; 37UBT-Higher Education Institution Prishtina, Kosovo; 38Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; 39Kilimanjaro Christian Medical University College, Moshi, 40Kibong’oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania; 41Cl´ınica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, M´exico City, Mexico; 42Department of Pulmonology of Central Hospital of Maputo, Maputo, 43Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique; 44Infectious Disease Translational Research Programme, Department of Medicine, National University of Singapore, Yong Loo Lin School of Medicine, Singapore, 45National University of Singapore Institute for Health Innovation & Technology (iHealthtech), Singapore, 46Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore; 47Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; 48Department of Biomedical Science, Faculty of Medicine, and 49Research Center for Care and Control of Infectious Disease (RC3iD), Universitas Padjadjaran, Bandung, 50Department of Internal Medicine, and 51Center for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 52Research, Innovation and Data Science Division, Rwanda Biomedical Center, Kigali, Rwanda; 53Instituto Vaccarezza, Hospital Mu˜ niz, Buenos Aires, Argentina; 54National Institute of Tuberculosis & Respiratory Diseases, New Delhi, India; 55National Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Faculty of Health, Catholic University, Ruˇzomberok, Vyˇsn´e Ha´gy, Slovakia; 56Department of Pulmonary Immunology, University of Texas Health Science Centre at Tyler, Tyler, TX, USA; 57Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands; 58Institute of Epidemiology and Healthcare, University College London, London, 59Find and Treat, University College Hospitals NHS Foundation Trust, London, UK; 60Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 61Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 62P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India; 63Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 64TB Competence Center, Swiss Lung Association, Berne, Switzerland Correspondence to: Onno WAkkermann, University of Groningen, University Medical Center Groningen, TB center Beatrixoord, Haren, and University of Groningen, University Medical Center Groningen, Department of Pulmonary diseases and Tuberculosis, Groningen, the Netherlands. email: o.w.akkerman@ umcg.nl.BACKGROUND: The aim of these clinical standards is to provide guidance on ‘best practice’ for diagnosis, treatment and management of drug-susceptible pulmonary TB (PTB). METHODS : A panel of 54 global experts in the field of TB care, public health, microbiology, and pharmacology were identified; 46 participated in a Delphi process. A 5- point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all 46 participants. R E SULT S : Seven clinical standards were defined: Standard 1, all patients (adult or child) who have symptoms and signs compatible with PTB should undergo investigations to reach a diagnosis; Standard 2, adequate bacteriological tests should be conducted to exclude drug-resistant TB; Standard 3, an appropriate regimen recommended by WHO and national guidelines for the treatment of PTB should be identified; Standard 4, health education and counselling should be provided for each patient starting treatment; Standard 5, treatment monitoring should be conducted to assess adherence, follow patient progress, identify and manage adverse events, and detect development of resistance; Standard 6, a recommended series of patient examinations should be performed at the end of treatment; Standard 7, necessary public health actions should be conducted for each patient.We also identified priorities for future research into PTB. CONCLUS ION: These consensus-based clinical standards will help to improve patient care by guiding clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment for PTB.